# EDGAR Filing Document

**Accession Number:** 0001910594
**File Stem:** 0001910594-23-000001
**Filing Date:** 2023-3
**Character Count:** 27887
**Document Hash:** ae18784321b88aba8afdb804542a0e37
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001910594-23-000001.hdr.sgml**: 20230331

**ACCESSION NUMBER**: 0001910594-23-000001

**CONFORMED SUBMISSION TYPE**: 1-SA

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230331

**DATE AS OF CHANGE**: 20230331

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Facible BioDiagnostics, Inc.
- **CENTRAL INDEX KEY:** 0001910594
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **IRS NUMBER:** 834324106
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 1-SA
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 24R-00672
- **FILM NUMBER:** 23789048

**BUSINESS ADDRESS:**
- **STREET 1:** 366 SW 5TH AVE
- **STREET 2:** STE 104
- **CITY:** MERIDIAN
- **STATE:** ID
- **ZIP:** 83642
- **BUSINESS PHONE:** 8013616686

**MAIL ADDRESS:**
- **STREET 1:** 366 SW 5TH AVE
- **STREET 2:** STE 104
- **CITY:** MERIDIAN
- **STATE:** ID
- **ZIP:** 83642

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FACbile BioDiagnostics LLC
- **DATE OF NAME CHANGE:** 20220210

Enter title of document 
```
<pre>
For

Facible BioDiagnostics, Inc.
A Delaware Corporation

I.R.S EIN: 882039154

Facible BioDiagnostics, Inc.
366 SW 5th Ave, Ste. 104
Meridian, ID 83642

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following is a statement by the management regarding the period of July 1, 2022, through December 31, 2022. The following statements balance sheets were prepared by the Company.
Item 1. Managements Discussion and Analysis of the Financial Condition and Results of Operations.
The following is a discussion of the financial condition of the Company. The Regulation A offering that was qualified by the SEC on 07-28-2022 was suspended on 11/16/2022 by management due to lack of investment due to unfavorable market conditions. Management decided to terminate employees related to operations and marketing to reduce salary burden. Five scientists remained through the end of the year to work on advancing the technology and readying it for a demonstration for a potential investor in February. Funds were secured using a SAFE note and secured bridge loans to the company. Efforts to secure additional external investments and grant funding were exhausted without success.
Components of Results of Operations
The following discussion of our financial conditions and results of operations should be read in conjunction with the financial statements and the related notes included elsewhere in this report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. The Companys actual results could differ significantly from those discussed in the forward-looking statements. Unless otherwise indicated, the latest results discussed below are as of December 31, 2022
The Company is, and has been, solely focused on further development of the Q-LAAD Technology in addition to raising capital. As of the date of this report, the Company has never been profitable. In the second half 2022 (through December 31, 2022) the Company had a Net Loss of $395,102.
Loss from operations decreased by $433,774. This decrease comes from the termination of labor and costs to associated with continued Q-LAAD development and the capital raise.
As of the date of this report, the Company has not had revenues.
Operating Expenses
The Company classifies its Operating Expenses as research and development, salaries, contractor, and other compensation, depreciation and amortization, general and administrative, rent, legal and accounting, utilities and insurance, marketing and advertising, travel, and other expenses. In the second half of 2022 (through December 2022) the Company had Operating Expenses totaling of $395,102. This represents a decrease in Operating Expenses of $433,774 or 48% when compared to the first half of 2022. This decrease comes from the decreased labor costs to reduce sales resources and move resources to product development.
Research and Development Expense
The Companys research and development efforts are focused on the continued development of in-vitro BioDiagnostics, including in preparation of potential investor demonstration assay. Research and development expenses consist primarily of materials, equipment, and manufacturing costs to design, develop, and test the in-vitro BioDiagnostics assay. Also included are parts, tools and equipment acquired to produce prototypes for testing.
The Company anticipates that the Company will increase these expenses significantly upon a successful and significant investment of funds into the Company.
Salaries and benefits
In the second half 2022 (through December 30, 2022), the Company spent $206,624 on salaries, contractor, and other compensation expenses. This represents a decrease of $7,263 or 3%. The reason for this decrease is the reduction of staffing and based on lack of funding and shifted focus towards research and development for the potential investor demonstration.
Item 2. Other Information
Upon successful completion of the potential investor technology demonstration, the investor decided to decline investment into the Company. The Company's fundraising efforts have been exhausted and the board has authorized an orderly liquidation of its assets. As a result, all employees were to be terminated no later than April 31, 2023. A shareholder meeting was held on 03/14/2023 and a unanimous vote was obtained for dissolution. Dissolution was unanimously approved by the board of directors on 3/20/2023. The Company has terminated all employees and ceased operations effective of 03/31/2023. In addition to ceasing operations, the Company has file a concurrent SEC form 1-Z to suspend ongoing reporting requirements, in addition to this SEC form 1-SA.
The financial statements included as Item 3 were compiled by a party that has no first-hand knowledge of the company, and that while reasonable efforts were made, it is possible claims may be asserted by stakeholders that are not yet recorded in the enclosed financial statements.
Facible BioDiagnostics Inc.
Balance Sheet
As of December 31, 2022

ASSETS
   Current Assets
      Bank Accounts
         1000-00 Cash and Cash Equivalents
            1010-00 FACible FIB Checking	43,446.22
            1020-00 FACible Main (6579)	4.32
         Total 1000-00 Cash and Cash Equivalents	$                        43,450.54
      Total Bank Accounts	$                        43,450.54
      Accounts Receivable
         1200-00 Accounts Receivable (A/R)	0.00
      Total Accounts Receivable	$                                 0.00
      Other Current Assets
         1310-00 Inventory Asset	88,303.73
         Total 1400-00 Prepaid Expenses	$                      101,634.39
      Total Other Current Assets	$                      189,938.12
   Total Current Assets	$                      233,388.66
   Fixed Assets
      1500-00 Fixed Assets
         1510-00 Furniture	20,599.81
         1520-00 Lab Equipment	907,872.53
         1530-00 Improvements	19,865.60
         1590-00 Accumulated Depreciation	-280,240.12
      Total 1500-00 Fixed Assets	$                      668,097.82
      1600-00 Intangible Assets - All
         1611-00 Patents	110,989.50
         1612-00 Website Development	11,972.20
         1620-00 Intellectual Property
            1620-10 DNA aptamer - 137369.8002.WO00	824.00
            1620-20 Microfluidic chip - 137369.8004.US00	8,043.00
            1620-30 RNA aptamer - 137369.8001	166.00
         Total 1620-00 Intellectual Property	$                          9,033.00
         1690-00 Accumulated Amortization	-9,636.79
      Total 1600-00 Intangible Assets - All	$                      122,357.91
   Total Fixed Assets	$                      790,455.73
TOTAL ASSETS	$                   1,023,844.39
LIABILITIES AND EQUITY
   Liabilities
      Current Liabilities
         Accounts Payable
            2020-00 Accounts Payable (A/P)	57,525.61
         Total Accounts Payable	$                        57,525.61
         Credit Cards
            2310-00 Credit Card Payable 8965	0.00
            2320-00 Facible Capital One	27,206.94
         Total Credit Cards	$                        27,206.94
         Total Other Current Liabilities	-$                       18,142.00
      Total Current Liabilities	$                        66,590.55
      Long-Term Liabilities
Hawkins Irrevocable Trust	100,000.00
Other Long Term Debt	232,361.50
      Total Long-Term Liabilities	$                      332,361.50
   Total Liabilities	$                      398,952.05
   Equity
      3000-00 Company Stock
         3020-00 Preferred Series A, par $0.001	20,740.61
      Total 3000-00 Company Stock	$                        20,740.61
      3100-00 Additional Paid-In Capital
         3120-00 APIC - PS Series A-1 (3M Cap)	2,620,853.50
         3130-00 APIC - PS Series A-2 (8M Cap)	4,058,454.94
         3140-00 APIC - PS Series A-3 (20M Cap)	2,784,590.95
      Total 3100-00 Additional Paid-In Capital	$                   9,463,899.39
      3200-00 Capital - Steve Burden	1,925.35
      3500-00 Retained Earnings	-8,100,675.16
      3600-00 Vested Common Units	462,982.00
      3900-00 Opening Balance Equity	0.00
      Net Income	-1,223,979.85
   Total Equity	$                      624,892.34
TOTAL LIABILITIES AND EQUITY	$                   1,023,844.39

FACible BioDiagnostics
P&L
January - December 2022

Income
Total Income	$                                 0.00
Cost of Goods Sold
   5000-00 Cost of Goods Sold
      5100-00 Payroll Expenses
         5110-00 R&D Payroll Costs	161,505.52
         5140-00 Payroll Expenses - Taxes	13,780.10
         5145-00 Payroll Expenses - Workers Comp	964.41
      Total 5100-00 Payroll Expenses	$                      176,250.03
   Total 5000-00 Cost of Goods Sold	$                      176,250.03
   5200-00 Lab Supplies	38,258.22
      5220-00 Reagents	19,972.58
      5240-00 Targets	11,671.60
   Total 5200-00 Lab Supplies	$                        69,902.40
   5500-00 R & D Software	8,600.00
Total Cost of Goods Sold	$                      254,752.43
Gross Profit	-$                     254,752.43
Expenses
   6000-00 Advertising & Marketing	184,244.88
      6100-00 Payroll Expense	0.00
         6110-00 Payroll Expense - Labor	40,833.38
         6130-00 Payroll Expenses - Taxes	3,388.86
         6135-00 Payroll Expenses - Workers Comp	233.32
      Total 6100-00 Payroll Expense	$                        44,455.56
      6200-00 Consulting	29,675.00
      6400-00 Product Development	4,990.00
   Total 6000-00 Advertising & Marketing	$                      263,365.44
   7000-00 General & Administrative
      7100-00 Payroll Expenses
         7110-00 Payroll Expenses - Labor	121,097.37
         7130-00 Payroll Expenses - Taxes	9,719.53
         7135-00 Payroll Expenses - Workers Comp	766.68
         7140-00 Payroll Expenses -Medical/Dental/Vision Insurance	68,222.00
      Total 7100-00 Payroll Expenses	$                      199,805.58
      7400-00 General & Administrative - Facilities
         7410-00 Rent & Lease	72,636.00
         7420-00 Janitorial & Waste Removal	5,330.00
         7440-00 Utilities	10,038.07
         7450-00 Office Facilities and setup	3,429.00
         7460-00 Telephone Expenses	2,900.00
      Total 7400-00 General & Administrative - Facilities	$                        94,333.07
      7500-00 Office Operations
         7510-00 Office Supplies	1,810.73
      Total 7500-00 Office Operations	$                          1,810.73
   Total 7000-00 General & Administrative	$                      295,949.38
   7700-00 Expense Reimbursement Clearing	450.00
   7800-00 General & Administrative -General
      7810-00 Office Software	43,971.58
      7820-00 Legal & Professional Services	410,150.74
      7825-00 Payroll Service Provider Fee	10,103.56
      7830-00 Meals & Entertainment	2,594.08
      7831-00 Travel - Transportation	6,069.33
      7832-00 Travel - Lodging	778.61
      7834-00 Travel - Other	1,064.52
      7840-00 Shipping, Freight & Delivery	5,405.37
      7850-00 Bank Charges & Fees	9,117.95
      7860-00 Conferences	50.00
      7870-00 Equipment	2,991.99
      7875-00 Permits, Licenses & Fees	287.50
      7880-00 Depreciation Expense	92,781.37
      7885-00 Amortization Expense	5,178.46
   Total 7800-00 General & Administrative -General	$                      590,545.06
   8598-00 Uncategorized Expense	388.00
   8600-00 Taxes & Licenses	370.40
   Insurance	14,088.09
Total Expenses	$                   1,165,156.37
Net Operating Income	-$                  1,419,908.80
Other Income
   8100-00 Other Income
      8110-00 RADx Grant	6,875.27
      8190-00 Other Income	6,105.97
   Total 8100-00 Other Income	$                        12,981.24
Total Other Income	$                        12,981.24
Other Expenses
   8500-00 Other Expense
      8510-00 Interest Expense	6.69
      8591-00 Ask My Accountant	-182,954.40
   Total 8500-00 Other Expense	 $                    (182,947.71)
Total Other Expenses	 $                    (182,947.71)
Net Other Income	 $                      195,928.95
Net Income	 $                 (1,223,979.85)

FACible BioDiagnostics
Statement of Cash Flows
January - December 2022

OPERATING ACTIVITIES
   Net Income	 $                   (1,223,979.85)
   Total Adjustments to reconcile Net Income to Net Cash provided by operations:	 $                      (217,653.67)
Net cash provided by operating activities	 $                   (1,441,633.52)
INVESTING ACTIVITIES
Net cash provided by investing activities	 $                          22,508.89
FINANCING ACTIVITIES
Net cash provided by financing activities	 $                     1,013,461.51
Net cash increase for period	 $                      (405,663.12)
Cash at beginning of period	 $                        449,113.66
Cash at end of period	 $                          43,450.54

EXHIBITS

Exhibit Index

SIGNATURES

Pursuant to the requirements of Regulation A, the issuer certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form 1-SA and has duly caused this Offering Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Meridian, ID on September 27, 2022

ISSUER COMPANY LEGAL NAME AND ADDRESS:

Facible BioDiagnostics, Inc.
366 SW 5th Ave, Ste. 104
Meridian, ID 83642

This Offering Statement has been signed by the following persons in the capacities and on the dates indicated:

s/Dr. Steven Burden, Ph.D.
Chairman of the Board of Directors, CEO, President of Facible BioDiagnostics, Inc.
(Date): September 27, 2022
Location Signed: Meridian, ID

</pre>
```

### Attached PDF Documents

**Attachment 1:** `FBDx1SA2022.pdf`

For

# **Facible BioDiagnostics, Inc.**  
A Delaware Corporation

**I.R.S EIN: 882039154**

**Facible BioDiagnostics, Inc.**  
**366 SW 5$^{th}$ Ave, Ste. 104**  
**Meridian, ID 83642**

# **MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

The following is a statement by the management regarding the period of July 1, 2022, through December 31, 2022. The following statements balance sheets were prepared by the Company.

# **Item 1. Management's Discussion and Analysis of the Financial Condition and Results of Operations.**

The following is a discussion of the financial condition of the Company. The Regulation A offering that was qualified by the SEC on 07-28-2022 was suspended on 11/16/2022 by management due to lack of investment due to unfavorable market conditions. Management decided to terminate employees related to operations and marketing to reduce salary burden. Five scientists remained through the end of the year to work on advancing the technology and readying it for a demonstration for a potential investor in February. Funds were secured using a SAFE note and secured bridge loans to the company. Efforts to secure additional external investments and grant funding were exhausted without success.

# **Components of Results of Operations**

The following discussion of our financial conditions and results of operations should be read in conjunction with the financial statements and the related notes included elsewhere in this report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. The Company’s actual results could differ significantly from those discussed in the forward-looking statements. Unless otherwise indicated, the latest results discussed below are as of December 31, 2022

The Company is, and has been, solely focused on further development of the Q-LAAD Technology in addition to raising capital. As of the date of this report, the Company has never been profitable. In the second half 2022 (through December 31, 2022) the Company had a Net Loss of $395,102.

Loss from operations decreased by $433,774. This decrease comes from the termination of labor and costs to associated with continued Q-LAAD development and the capital raise.

As of the date of this report, the Company has not had revenues.

# **Operating Expenses**

The Company classifies its Operating Expenses as research and development, salaries, contractor, and other compensation, depreciation and amortization, general and administrative, rent, legal and accounting,

utilities and insurance, marketing and advertising, travel, and other expenses. In the second half of 2022 (through December 2022) the Company had Operating Expenses totaling of $395,102. This represents a decrease in Operating Expenses of $433,774 or 48% when compared to the first half of 2022. This decrease comes from the decreased labor costs to reduce sales resources and move resources to product development.

## Research and Development Expense

The Company’s research and development efforts are focused on the continued development of in-vitro BioDiagnostics, including in preparation of potential investor demonstration assay. Research and development expenses consist primarily of materials, equipment, and manufacturing costs to design, develop, and test the in-vitro BioDiagnostics assay. Also included are parts, tools and equipment acquired to produce prototypes for testing.

The Company anticipates that the Company will increase these expenses significantly upon a successful and significant investment of funds into the Company.

## Salaries and benefits

In the second half 2022 (through December 30, 2022), the Company spent $206,624 on salaries, contractor, and other compensation expenses. This represents a decrease of $7,263 or 3%. The reason for this decrease is the reduction of staffing and based on lack of funding and shifted focus towards research and development for the potential investor demonstration.

## Item 2. Other Information

Upon successful completion of the potential investor technology demonstration, the investor decided to decline investment into the Company. The Company’s fundraising efforts have been exhausted and the board has authorized an orderly liquidation of its assets. As a result, all employees were to be terminated no later than April 31, 2023. A shareholder meeting was held on 03/14/2023 and a unanimous vote was obtained for dissolution. Dissolution was unanimously approved by the board of directors on 3/20/2023. The Company has terminated all employees and ceased operations effective of 03/31/2023. In addition to ceasing operations, the Company has file a concurrent SEC form 1-Z to suspend ongoing reporting requirements, in addition to this SEC form 1-SA.

The financial statements included as Item 3 were compiled by a party that has no first-hand knowledge of the company, and that while reasonable efforts were made, it is possible claims may be asserted by stakeholders that are not yet recorded in the enclosed financial statements.

## **Facible BioDiagnostics Inc. Balance Sheet**

**As of December 31, 2022**

| ASSETS |  |
| --- | --- |
| Current Assets |  |
| Bank Accounts |  |
| 1000-00 Cash and Cash Equivalents |  |
| 1010-00 FACible FIB Checking | 43,446.22 |
| 1020-00 FACible Main (6579) | 4.32 |

| Total 1000-00 Cash and Cash Equivalents | $ | 43,450.54 |
| --- | --- | --- |
| Total Bank Accounts | $ | 43,450.54 |
| Accounts Receivable |  |  |
| 1200-00 Accounts Receivable (A/R) |  | 0.00 |
| Total Accounts Receivable | $ | 0.00 |
| Other Current Assets |  |  |
| 1310-00 Inventory Asset |  | 88,303.73 |
| Total 1400-00 Prepaid Expenses | $ | 101,634.39 |
| Total Other Current Assets | $ | 189,938.12 |
| Total Current Assets | $ | 233,388.66 |
| Fixed Assets |  |  |
| 1500-00 Fixed Assets |  |  |
| 1510-00 Furniture |  | 20,599.81 |
| 1520-00 Lab Equipment |  | 907,872.53 |
| 1530-00 Improvements |  | 19,865.60 |
| 1590-00 Accumulated Depreciation |  | -280,240.12 |
| Total 1500-00 Fixed Assets | $ | 668,097.82 |
| 1600-00 Intangible Assets - All |  |  |
| 1611-00 Patents |  | 110,989.50 |
| 1612-00 Website Development |  | 11,972.20 |
| 1620-00 Intellectual Property |  |  |
| 1620-10 DNA aptamer - 137369.8002.WO00 |  | 824.00 |
| 1620-20 Microfluidic chip - 137369.8004.US00 |  | 8,043.00 |
| 1620-30 RNA aptamer - 137369.8001 |  | 166.00 |
| Total 1620-00 Intellectual Property | $ | 9,033.00 |
| 1690-00 Accumulated Amortization |  | -9,636.79 |
| Total 1600-00 Intangible Assets - All | $ | 122,357.91 |
| Total Fixed Assets | $ | 790,455.73 |
| TOTAL ASSETS | $ | 1,023,844.39 |
| LIABILITIES AND EQUITY |  |  |
| Liabilities |  |  |
| Current Liabilities |  |  |
| Accounts Payable |  |  |
| 2020-00 Accounts Payable (A/P) |  | 57,525.61 |
| Total Accounts Payable | $ | 57,525.61 |
| Credit Cards |  |  |
| 2310-00 Credit Card Payable 8965 |  | 0.00 |
| 2320-00 Facible Capital One |  | 27,206.94 |
| Total Credit Cards | $ | 27,206.94 |
| Total Other Current Liabilities | -$ | 18,142.00 |
| Total Current Liabilities | $ | 66,590.55 |
| Long-Term Liabilities |  |  |
| Hawkins Irrevocable Trust |  | 100,000.00 |

| Other Long Term Debt | 232,361.50 |
| --- | --- |
| Total Long-Term Liabilities | $332,361.50 |
| Total Liabilities | $398,952.05 |
| Equity |  |
| 3000-00 Company Stock |  |
| 3020-00 Preferred Series A, par $0.001 | 20,740.61 |
| Total 3000-00 Company Stock | $20,740.61 |
| 3100-00 Additional Paid-In Capital |  |
| 3120-00 APIC - PS Series A-1 (3M Cap) | 2,620,853.50 |
| 3130-00 APIC - PS Series A-2 (8M Cap) | 4,058,454.94 |
| 3140-00 APIC - PS Series A-3 (20M Cap) | 2,784,590.95 |
| Total 3100-00 Additional Paid-In Capital | $9,463,899.39 |
| 3200-00 Capital - Steve Burden | 1,925.35 |
| 3500-00 Retained Earnings | -8,100,675.16 |
| 3600-00 Vested Common Units | 462,982.00 |
| 3900-00 Opening Balance Equity | 0.00 |
| Net Income | -1,223,979.85 |
| Total Equity | $624,892.34 |
| TOTAL LIABILITIES AND EQUITY | $1,023,844.39 |

## FACible BioDiagnostics P&L

January - December 2022

| Income |  |
| --- | --- |
| Total Income | $0.00 |
| Cost of Goods Sold |  |
| 5000-00 Cost of Goods Sold |  |
| 5100-00 Payroll Expenses |  |
| 5110-00 R&D Payroll Costs | 161,505.52 |
| 5140-00 Payroll Expenses - Taxes | 13,780.10 |
| 5145-00 Payroll Expenses - Workers Comp | 964.41 |
| Total 5100-00 Payroll Expenses | $176,250.03 |
| Total 5000-00 Cost of Goods Sold | $176,250.03 |
| 5200-00 Lab Supplies | 38,258.22 |
| 5220-00 Reagents | 19,972.58 |
| 5240-00 Targets | 11,671.60 |
| Total 5200-00 Lab Supplies | $69,902.40 |
| 5500-00 R & D Software | 8,600.00 |
| Total Cost of Goods Sold | $254,752.43 |
| Gross Profit | -$254,752.43 |
| Expenses |  |
| 6000-00 Advertising & Marketing | 184,244.88 |

| 6100-00 Payroll Expense |  | 0.00 |
| --- | --- | --- |
| 6110-00 Payroll Expense - Labor |  | 40,833.38 |
| 6130-00 Payroll Expenses - Taxes |  | 3,388.86 |
| 6135-00 Payroll Expenses - Workers Comp |  | 233.32 |
| Total 6100-00 Payroll Expense | $ | 44,455.56 |
| 6200-00 Consulting |  | 29,675.00 |
| 6400-00 Product Development |  | 4,990.00 |
| Total 6000-00 Advertising & Marketing | $ | 263,365.44 |
| 7000-00 General & Administrative |  |  |
| 7100-00 Payroll Expenses |  |  |
| 7110-00 Payroll Expenses - Labor |  | 121,097.37 |
| 7130-00 Payroll Expenses - Taxes |  | 9,719.53 |
| 7135-00 Payroll Expenses - Workers Comp |  | 766.68 |
| 7140-00 Payroll Expenses -Medical/Dental/Vision Insurance |  | 68,222.00 |
| Total 7100-00 Payroll Expenses | $ | 199,805.58 |
| 7400-00 General & Administrative - Facilities |  |  |
| 7410-00 Rent & Lease |  | 72,636.00 |
| 7420-00 Janitorial & Waste Removal |  | 5,330.00 |
| 7440-00 Utilities |  | 10,038.07 |
| 7450-00 Office Facilities and setup |  | 3,429.00 |
| 7460-00 Telephone Expenses |  | 2,900.00 |
| Total 7400-00 General & Administrative - Facilities | $ | 94,333.07 |
| 7500-00 Office Operations |  |  |
| 7510-00 Office Supplies |  | 1,810.73 |
| Total 7500-00 Office Operations | $ | 1,810.73 |
| Total 7000-00 General & Administrative | $ | 295,949.38 |
| 7700-00 Expense Reimbursement Clearing |  | 450.00 |
| 7800-00 General & Administrative -General |  |  |
| 7810-00 Office Software |  | 43,971.58 |
| 7820-00 Legal & Professional Services |  | 410,150.74 |
| 7825-00 Payroll Service Provider Fee |  | 10,103.56 |
| 7830-00 Meals & Entertainment |  | 2,594.08 |
| 7831-00 Travel - Transportation |  | 6,069.33 |
| 7832-00 Travel - Lodging |  | 778.61 |
| 7834-00 Travel - Other |  | 1,064.52 |
| 7840-00 Shipping, Freight & Delivery |  | 5,405.37 |
| 7850-00 Bank Charges & Fees |  | 9,117.95 |
| 7860-00 Conferences |  | 50.00 |
| 7870-00 Equipment |  | 2,991.99 |
| 7875-00 Permits, Licenses & Fees |  | 287.50 |
| 7880-00 Depreciation Expense |  | 92,781.37 |
| 7885-00 Amortization Expense |  | 5,178.46 |
| Total 7800-00 General & Administrative -General | $ | 590,545.06 |
| 8598-00 Uncategorized Expense |  | 388.00 |

| 8600-00 Taxes & Licenses | 370.40 |
| --- | --- |
| Insurance | 14,088.09 |
| Total Expenses | $1,165,156.37 |
| Net Operating Income | -$1,419,908.80 |
| Other Income |  |
| 8100-00 Other Income |  |
| 8110-00 RADx Grant | 6,875.27 |
| 8190-00 Other Income | 6,105.97 |
| Total 8100-00 Other Income | $12,981.24 |
| Total Other Income | $12,981.24 |
| Other Expenses |  |
| 8500-00 Other Expense |  |
| 8510-00 Interest Expense | 6.69 |
| 8591-00 Ask My Accountant | -182,954.40 |
| Total 8500-00 Other Expense | $(182,947.71) |
| Total Other Expenses | $(182,947.71) |
| Net Other Income | $195,928.95 |
| Net Income | $(1,223,979.85) |

## FACible BioDiagnostics Statement of Cash Flows

January - December 2022

| OPERATING ACTIVITIES |  |
| --- | --- |
| Net Income | $(1,223,979.85) |
| Total Adjustments to reconcile Net Income to Net Cash provided by operations: | $(217,653.67) |
| Net cash provided by operating activities | $(1,441,633.52) |
| INVESTING ACTIVITIES |  |
| Net cash provided by investing activities | $22,508.89 |
| FINANCING ACTIVITIES |  |
| Net cash provided by financing activities | $1,013,461.51 |
| Net cash increase for period | $(405,663.12) |
| Cash at beginning of period | $449,113.66 |
| Cash at end of period | $43,450.54 |

## EXHIBITS

### Exhibit Index

## SIGNATURES

Pursuant to the requirements of Regulation A, the issuer certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form 1-SA and has duly caused this Offering Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Meridian, ID on September 27, 2022

ISSUER COMPANY LEGAL NAME AND ADDRESS:

**Facible BioDiagnostics, Inc.**

366 SW 5th Ave, Ste. 104
Meridian, ID 83642

This Offering Statement has been signed by the following persons in the capacities and on the dates indicated:

s/Dr. Steven Burden, Ph.D.

Chairman of the Board of Directors, CEO, President of Facible BioDiagnostics, Inc.

(Date): September 27, 2022

Location Signed: Meridian, ID